Donor Bisphosphonate Treatment Negatively Impacts Mineralized Allografts, Animal Study Finds
The findings of a new animal study suggest that bisphosphonate treatment in donors may indeed be relevant when mineralized allografts …
What’s New in Osteoporosis and Fragility Fractures 2022
The recent JBJS Guest Editorial “What’s New in Osteoporosis and Fragility Fractures” provides an update on this important …
JBJS Editor’s Choice: Improving Function After Fragility Fractures
In the past several years, the orthopaedic community has become highly engaged in improving the follow-up management of patients presenting …
Atypical Femoral Fractures: An Update
We posted our first “Case Connections” article about bisphosphonate-related atypical femoral fractures (AFFs) one year ago. Since then, JBJS Case …
What’s New in Limb Lengthening/Deformity Correction: Level I and II Studies
Every month, JBJS publishes a Specialty Update—a review of the most pertinent and impactful studies published in the orthopaedic literature …
JBJS Reviews Editor’s Choice–Bisphosphonate-Related Femoral Fractures
In December 1996, a group of investigators reported the results of the Fracture Intervention Trial, a randomized controlled trial that …
Preventing Atypical Femoral Fractures Related to Bisphosphonates
Physicians worldwide frequently prescribe bisphosphonates such as alendronate (Fosamax) and ibandronate (Boniva) to treat osteoporosis and prevent fragility fractures. Unfortunately, …
Another Look at Bisphosphonates and Jaw Osteonecrosis
A recent study in the Journal of Clinical Endocrinology & Metabolism found that approximately one out of 200 Taiwanese who …